Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study.

In our current study, CP transfusion was clinically safe based on the safety profile; however, the clinical benefit was not significant in critically ill patients with more comorbidities at the late stage of disease during a 28-day observation.